In a mouse pancreatic cancer model, inhibition of IL‐17‐stimulated NETosis has shown potent anti‐cancer effects and enhances sensitivity to ICIs (PD1, CTLA4) [61]. This evidence concerns the gene CTLA4 and familial pancreatic carcinoma.